Request Trial

Marisa Woutersen

Key details

Marisa Woutersen is a senior reporter for Life Sciences Intellectual Property Review and World IP Review. She largely covers intellectual property developments across the global life sciences sector, including pharmaceuticals, biotechnology, medtech, AI, M&A and regulation.

Since joining Newton Media in 2023, Marisa has reported across a wide range of topics, from the rise of generative AI and its impact on the creative industries to the crossover between intellectual property and sport, including issues affecting athletes, as well as global pharmaceutical disputes, vaccine technology, access to medicines and life sciences M&A.

She has reported live from court and regularly travels to international conferences, where she interviews lawyers, business leaders and other key industry figures.

Marisa holds a Master’s in International Law and a BA in Politics and International Relations from the University of Sussex, and is currently completing her NCTJ Diploma in Journalism.

Reset all filters
Article Type
Channels & Sectors
Geography
Company
Refine search
Total results: 456

Articles by Marisa Woutersen

Gene tech firm fends off injunction in test kit dispute
Americas
Gene tech firm fends off injunction in test kit dispute
New England Biolab contends plaintiff’s patents are invalid and cover “unpatentable natural processes”| Biomodal had accused rival of infringing several patents covering methods to detect and modify DNA methylatian—a key part of epigenetic research   28 November 2024
EPO invalidates human milk patent after Nestle opposition
Europe
EPO invalidates human milk patent after Nestle opposition
European panel deals blow to a biotech company over human milk oligosaccharides used in infant formula | Patent opposed by giant Nestlé, FrieslandCampina, and Danisco questioning its inventive step.   26 November 2024
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
Europe
EPO delivers key Novo Nordisk, GSK and Inhibrx rulings
European Patent Office deals blow to pharma companies in dismissing their attempts to reinstate patents covering diabetes and obesity treatments | Inhibrx antibody patent upheld as Gilead subsidiary appeal is rejected.   21 November 2024
Careers
Paul, Weiss swoops for senior duo from Weil, Gotshal
The firm brings two life sciences and tech experts to its litigation department | Pair bring combined experience of 45 years from Weil, Gotshal & Manges | Duo offer expertise handling cases for pharmaceutical, biotechnology, and technology clients.   21 November 2024
Europe
GSK triumphs in EPO appeal, revoking Pfizer patent
European patent related to an inhaler revoked following successful appeal by GSK | Ruling comes after a series of challenges over novelty and inventive step | Decision further intensifies ongoing patent disputes between the pharma giants.   14 November 2024
Europe
CRISPR patents revoked following Nobel Prize winners’ withdrawal
The patents have been officially revoked following the pair's voluntary decision to withdraw them | Withdrawal follows unfavourable preliminary opinion from the EPO | Cancelled patents not expected to impact ongoing licensing agreements for CRISPR technology, says licensor.   12 November 2024
Americas
Sanofi subsidiary fends off $450m trade secrets case
A jury in Delaware unanimously dismissed all allegations of misappropriation against Inhibrx, a Sanofi-owned biotech firm | Case stemmed from a previous arbitration involving the chief scientific officer of Inhibrx | Jury found no evidence supporting opponents claims, awarding the plaintiff $0 damages.   5 November 2024
Americas
Regulatory expert joins White & Case
New hire specialises in guiding life sciences and health tech clients through compliance issues | Work includes US regulations, including those enforced by the FDA, Drug Enforcement Administration and the Office of Inspector General.   31 October 2024
Europe
Cooley adds ex-Gowling partner
Former head of life sciences at Gowling, joins Cooley’s London office as a partner | Brings expertise in cross-border licensing and collaboration deals in the pharmaceutical, biotech, and medical device sectors.   29 October 2024
Americas
Apple wins just $250 in Masimo smartwatch clash
A federal jury finds Masimo’s smartwatches infringe Apple’s blood oxygen patents | Decision results in an award of just $250 for the tech giant | Despite the victory, Masimo says the ruling does not apply to its current products.   29 October 2024

Not finding what you're looking for, please try resetting your applied search and filters,
or try the full site search.